Protective effect of extract of Boerhaavia diffusa and Silybum marianum in combination against fructose induced non‑alcoholic fatty liver in rats

Sachin Jain, Kamna S. Tripathi, Gaurav Parihar, Praveen Sharma, Aakash Singh Panwar

Abstract


Aim: The present study was undertaken with a view to validate the traditional use of Boerhaavia diffusa (BEE) root and Silybum marianum (SME) seeds in combination as a hepatoprotective agent against non‑alcoholic fatty liver disease. Materials and Methods: The alcoholic extracts of BEE roots (150 mg/kg, p.o.) and SME (150 mg/kg, p.o.) seeds were administered to the experimental rats individually and in combination (75 mg/kg + 75 mg/kg), p.o. by dispersing it in 1% tween 80, were given, of different groups respectively. After intoxication with
high fructose diet (HFD) fructose solution to the animals orally for 6 weeks serum levels of various enzymes were recorded. Serum levels of aspartate transaminase (AST), alanine amino transaminase (ALT), alkaline phosphatase (ALP), total bilirubin (TB), total protein and cholesterol (CHO) level were assessed. Results: BEE roots and SME seeds extracts exhibited a significant hepatoprotective effect as evident from the decreases of serum AST, ALT, ALP, TB and CHO and increases in levels of TP compared with control group (P < 0.01 or P < 0.05).
The effect of combination of both the extract exerts more hepatoprotective as revealed by more level of significance. Conclusions: The present finding suggests that the hepatoprotective effect of BEE roots and SME seeds extract.
Key words: Boerhaavia diffusa, fructose, hepatoprotective, non‑alcoholic fatty liver, silybum marianum

Full Text:

PDF

References


Shanmugarajan TS, Sivaraman D, Somasundaram I, Arunsundar M,

Krishnakumar E, Balaji R, et al. Influence of alpha lipoic acid on

antioxidant status in D‑galactosamine‑induced hepatic injury.

Toxicol Ind Health 2008;24:635‑42.

Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic

steatohepatitis: Mayo clinic experiences with a hitherto unnamed

disease. Mayo Clin Proc 1980;55:434‑8.

Rodríguez‑Hernández H, Gonzalez JL, Márquez‑Ramirez MD,

Flores‑Hernandez M, Rodríguez‑Morán M, Guerrero‑Romero F.

Risk factors associated with nonalcoholic fatty liver disease

and its relationship with the hepatic histological changes. Eur J

Gastroenterol Hepatol 2008;20:399‑403.

Verrijken A, Francque S, Van Gaal L. The metabolic syndrome and

the liver. Acta Gastroenterol Belg 2008;71:48‑59.

Stefan N, Kantartzis K, Häring HU. Causes and metabolic

consequences of Fatty liver. Endocr Rev 2008;29:939‑60.

Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C,

American Heart Association, et al. Definition of metabolic

syndrome: Report of the National Heart, Lung, and Blood Institute/

American Heart Association conference on scientific issues related

to definition. Circulation 2004;109:433‑8.

Stern MP, Williams K, González‑Villalpando C, Hunt KJ,

Haffner SM. Does the metabolic syndrome improve identification

of individuals at risk of type 2 diabetes and/or cardiovascular

disease? Diabetes Care 2004;27:2676‑81.

Anderson PJ, Critchley JA, Chan JC, Cockram CS, Lee ZS,

Thomas GN, et al. Factor analysis of the metabolic syndrome:

Obesity vs insulin resistance as the central abnormality. Int J Obes

Relat Metab Disord 2001;25:1782‑8.

Holvoet P. Relations between metabolic syndrome, oxidative

stress and inflammation and cardiovascular disease. Verh K Acad

Geneeskd Belg 2008;70:193‑219.

Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: Present

and emerging therapies. Semin Liver Dis 2001;21:81‑8.

Drenick EJ, Simmons F, Murphy JF. Effect on hepatic morphology

of treatment of obesity by fasting, reducing diets and small‑bowel

bypass. N Engl J Med 1970;282:829‑34.

CSIR. The Wealth of India: Raw Materials. Vol. 7B. CSIR:

New Delhi, India; 1988. p. 174.

Dhar ML, Dhar MM, Dhawan BN, Mehrotra BN, Ray C. Screening of

Indian plants for biological activity: I. Indian J Exp Biol 1968;6:232‑47.

Chandan BK, Sharma AK, Anand KK. Boerhaavia diffusa: A study

of its hepatoprotective activity. Indian J Exp Biol 1991;31:299‑307.

Rawat AK, Mehrotra S, Tripathi SC, Shome U. Hepatoprotective

activity of Boerhaavia diffusa L. roots – A popular Indian

ethnomedicine. J Ethnopharmacol 1997;56:61‑6.

Gaitonde BB, Kulkarni HJ, Nabar SD. Diuretic activity of

punarnava (Boerhaavia diffusa). Bull Haffkine (Bombay, India)

;2:24.

Bhalla TN, Gupta MB, Sheth PK, Bhargava KP. Anti‑inflammatory

activity of Boerhaavia diffusa. Indian J Physiol Pharmacol

;12:37.

Jain GK, Khanna NM. Punarnavoside: A new antifibrinolytic agent

from Boerhaavia diffusa. Indian J Chem 1989;28:163‑6.

Adesina SK. Anticonvulsant properties of the roots of Boerhaavia

diffusa. Q J Crude Drug Res 1979;17:84‑6.

Olukoya DK, Idika N, Odugbemi T. Antibacterial activity

of some medicinal plants from Nigeria. J Ethnopharmacol

;39:69‑72.

Agarwal R, Agarwal C, Ichikawa H, Singh RP, Aggarwal BB.

Anticancer potential of silymarin: From bench to bed side.

Anticancer Res 2006;26:4457‑98.

Giese LA. Milk thistle and the treatment of hepatitis. Gastroenterol

Nurs 2001;24:95‑7.

Jeong DH, Lee GP, Jeong WI, Do SH, Yang HJ, Yuan DW, et al.

Alterations of mast cells and TGF‑beta1 on the silymarin treatment

for CCl (4)‑induced hepatic fibrosis. World J Gastroenterol

;11:1141‑8.

Zielińska‑Przyjemska M, Wiktorowicz K. An in vitro study of the

protective effect of the flavonoid silydianin against reactive oxygen

species. Phytother Res 2006;20:115‑9.

Dehmlow C, Erhard J, de Groot H. Inhibition of Kupffer cell

functions as an explanation for the hepatoprotective properties

of silibinin. Hepatology 1996;23:749‑54.

Mukherjee PK. Quality Control of Herbal Drugs. Culcu􀄴 a: Business

Horizons; 2002. p. 184-205, 529-34, 562-7.

OECD Guideline for testing of chemicals, acute oral toxicity – Fixed

dose procedure, 420. Organization for economic co-operation and

development; 2001.

Sharma A, Chakraborti KK, Handa SS. Anti hepatotoxic activity

of some Indian herbal formulations as compared to silymarin.

Fitoterapia 1991;62:229-35.

Reitman S, Frankel S. A colorimetric method for the determination

of serum glutamic oxalacetic and glutamic pyruvic transaminases.

Am J Clin Pathol 1957;28:56-63.

Henary RJ, Cannon DC, Winkleman JW. Clinical Chemistry

Principles and Techniques. 2nd ed. Maryland: Harper and Roe; 1974.

Fredrikson DS, Levi RL, Less RS. Determination of cholesterol.

N Engl J Med 1967;276:148-56.

Shrivastava N, Padhya MA. “Punarnavine” profile in the

regenerated roots of Boerhaavia diff usa L. from leaf segments. Curr

Sci 1995;68:653-6.

Luper S. A review of plants used in the treatment of liver disease:

Part 1. Altern Med Rev 1998;3:410-21.

Stipanuk MH. Biochemical, Physiological, and Molecular

Aspects of Human Nutrition. 2nd ed. Philadelphia, PA: Elsevier,

W.B. Saunders; 2006.

Wikipedia, the free encyclopedia; fructose. Available from:

h􀄴 p://en.wikipedia.org/wiki/Fructose# citenote-22. [Last accessed

on 2010 Oct 25].

Chaudhari BP, Chaware VJ, Joshi YR, Biyani KR. Hepatoprotective

activity of hydroalcoholic extract of Momordica charantia Linn.

leaves against carbon tetra chloride induced hepatopathy in rats.

Int J ChemTech Res 2009;1:355-8.




DOI: http://dx.doi.org/10.22377/ijgp.v7i3.328

Refbacks

  • There are currently no refbacks.